Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 202


Home  | About Us | Editors | Search | Ahead Of Print | Current Issue | Archives | Submit Article | Instructions | Subscribe | Contacts | Login 
Year : 2021  |  Volume : 11  |  Issue : 2  |  Page : 67-72

Safety and efficacy of thromboelastography guidance of antifibrinolytic therapy in trauma patients: An observational cohort analysis

1 Department of Pharmacy, OhioHealth Doctors Hospital, Columbus, Ohio, USA
2 Department of Trauma, OhioHealth Grant Medical Center, Columbus, Ohio, USA
3 Department of Pharmacy, OhioHealth Grant Medical Center, Columbus, Ohio, USA
4 Department of Research, OhioHealth Research and Innovation Institute, Columbus, Ohio, USA

Correspondence Address:
Dr. Rachel N Heilbronner
Department of Pharmacy, OhioHealth Doctors Hospital, 5100 West Broad Street, Columbus 43228, Ohio
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/IJCIIS.IJCIIS_79_20

Rights and Permissions

Background: Tranexamic acid (TXA) is an antifibrinolytic therapy intended to decrease blood loss and improve hemostasis in traumatic hemorrhage. Viscoelastic assays, such as thromboelastography (TEG), allow for the identification of a patient's specific hemostasis. The purpose of this research study was to explore the safety and efficacy of TEG-guided antifibrinolytic therapy in trauma patients. Methods: This study was a retrospective review of trauma patients meeting institution-specific inclusion criteria for TXA. Patients were assigned to fibrinolytic groups per TEG LY30 data. Safety outcomes (24-h mortality, overall in-hospital mortality, and thromboembolic events) were compared between patients who did or did not receive TXA and within fibrinolytic groups. Mortality outcomes were adjusted for baseline Injury Severity Score (ISS). Secondary aims included blood product utilization, length of hospital, and intensive care unit stay. Results: Hypofibrinolysis was the most common fibrinolytic phenotype. Adjusting for ISS, there were no significant differences in mortality. A 30.7% thromboembolism incidence was identified in the TXA group compared to 16.6% not receiving TXA (P = 0.26), with 72.7% of these patients experiencing fibrinolytic shutdown. Conclusions: There were no differences in 24-h mortality, all-cause mortality, or secondary outcomes. The difference in thromboembolic rates between patients receiving TXA and those who did not, while not statistically significant, poses clinical concern.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal